Format

Send to

Choose Destination
Int J Clin Exp Med. 2015 Aug 15;8(8):13329-34. eCollection 2015.

Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression.

Author information

1
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University Anhui, China.

Abstract

OBJECTIVE:

The aim of this study is to investigate the sensitivity change and the preliminary mechanism of ovarian cancer cells on the resistant to chemotherapeutic drugs by inhibiting miR-23a expression.

METHODS:

The ovarian cancer cell lines A2780 was administrated with antagomir-23a and platinum, and then the cell proliferation inhibition rate was determined by MTT assay. The cell cycle distribution was detected by flow cytometric analysis. The apoptotic morphological changes were analyzed by Hoechst33258 staining. The glycoprotein P-gp expression changes were detected by Western blot analysis.

RESULTS:

The cell proliferation inhibition rate increased significantly after the administration of miR-23a and platinum (P<0.01). The middle concentration of drug efficacy IC50 in experimental group decreased by 83.76% compared with that in control group, which was 17.89 μmol/L vs 110.18 μmol/L (P<0.01). The cell lines A2780 were arrested in G0/G1 phase and apoptosis rate kept increasing (P<0.05). The cell nuclei stained by Hoechst33258 were obviously enhanced and demonstrated apoptosis morphology, such as condense, pyknosis. Compared with control group, the levels of P-gp protein expression in experimental group decreased along with the increase of the cisplatin concentration (P<0.05).

CONCLUSION:

The inhibition of miR-23a expression could significantly increase the sensitivity of cisplatin towards tumor cells, and it was probably because the negative regulatory factors of miR-23a target genes was released, and as a result, the expression of P-gp protein was inhibited.

KEYWORDS:

MicroRNA; cisplatin; drug resistance; ovarian cancer

PMID:
26550261
PMCID:
PMC4612946

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center